To determine the possible role of COX-2 in motility dysfunction in obstruction and after obstruction is resolved, we administered COX-2 inhibitor NS-398 (5 mg/kg, i.p. daily) during BO and in the post-BO state in separate studies. This evidence concerns the gene PTGS2 and bronchiolitis obliterans syndrome.